A detailed history of Rhumbline Advisers transactions in Purple Biotech Ltd. stock. As of the latest transaction made, Rhumbline Advisers holds 16 shares of PPBT stock, worth $5. This represents 0.0% of its overall portfolio holdings.

Number of Shares
16
Previous 555 97.12%
Holding current value
$5
Previous $0 NaN%
% of portfolio
0.0%
Previous 0.0%

Shares

2 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q1 2024

May 09, 2024

SELL
$0.58 - $0.92 $312 - $495
-539 Reduced 97.12%
16 $0
Q2 2023

Aug 08, 2023

BUY
$1.38 - $2.05 $765 - $1,137
555 New
555 $0

Others Institutions Holding PPBT

About PURPLE BIOTECH LTD.


  • Ticker PPBT
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 18,303,300
  • Market Cap $6.77M
  • Description
  • Purple Biotech Ltd., a clinical-stage company, focuses on developing therapies to overcome tumor immune evasion and drug for cancer patients in the United States. Its oncology pipeline includes CM24, a monoclonal antibody that blocks carcinoembryonic antigen related cell adhesion molecule 1 as a combination therapy with anti-PD-1 checkpoint inhi...
More about PPBT
Track This Portfolio

Track Rhumbline Advisers Portfolio

Follow Rhumbline Advisers and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Rhumbline Advisers, based on Form 13F filings with the SEC.

News

Stay updated on Rhumbline Advisers with notifications on news.